Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Investor World Review.
Press releases published on May 14, 2025
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewswire
·
May 14, 2025
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to Baseline Key endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index ( …
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
GlobeNewswire
·
May 14, 2025
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 (GLOBE …
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire
·
May 14, 2025
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann …
Stallion Uranium Announces Failure to File Cease Trade Order
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) announces that the British Columbia Securities Commission (the "BCSC"), as the principal regulator of …
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
GlobeNewswire
·
May 14, 2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
nCino Announces Timing of its First Quarter Fiscal Year 2026 Financial Results Conference Call
GlobeNewswire
·
May 14, 2025
WILMINGTON, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, will report financial results for its first quarter ended April 30, 2025, after the market close on …
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports interim data readout expected in the second half of …
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
GlobeNewswire
·
May 14, 2025
Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operations Enrollment in LAVA-1266 Phase 1 continues to progress Cash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 …
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of …
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 14, 2025
- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first …
Erdene Announces Q1 2025 Results and Provides Bayan Khundii Project Update
GlobeNewswire
·
May 14, 2025
HALIFAX, Nova Scotia, May 14, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) ("Erdene" or the "Company") is pleased to announce operating and financial results for the quarter ended March 31, 2025, and to provide an update …
[Latest] Global Pharmaceutical Container Market Size/Share Worth USD 189.45 Billion by 2034 at a 6.98% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
GlobeNewswire
·
May 14, 2025
Austin, TX, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pharmaceutical Container Market Size, Trends and Insights By Product Type (Bottles, Vials …
PussFi Launches $PUSS: Turning Memes into Real-Utility Tokens!
GlobeNewswire
·
May 14, 2025
DUBAI, United Arab Emirates, May 14, 2025 (GLOBE NEWSWIRE) -- PussFi has officially launched $PUSS, the first-ever meme-tility token (a meme coin with real-world utility), on Steemit, a decentralized social media platform. Built on the Tron blockchain, $ …
Kornit Digital Reports First Quarter 2025 Results
GlobeNewswire
·
May 14, 2025
First quarter revenues of $46.5 million, in line with previous guidance First quarter GAAP net loss of $5.1 million; non-GAAP net income of $0.6 million Continued to generate cash from operations, demonstrating disciplined execution Reported annual …
Crown Crafts Announces Quarterly Cash Dividend
GlobeNewswire
·
May 14, 2025
GONZALES, La., May 14, 2025 (GLOBE NEWSWIRE) -- Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) announced today that its Board of Directors has declared a quarterly cash dividend on its Series A common stock of $0.08 per share to be paid on July 3, …
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated …
Peter Lambrinakos, O.O.M., CPP, Joins Draganfly’s Public Safety Advisory Board, Strengthening Canadian Leadership in Public Safety
GlobeNewswire
·
May 14, 2025
Veteran leader in public safety, national security, and critical infrastructure protection brings strategic, operational, and innovation expertise to advance Draganfly’s public safety mission Saskatoon, SK, May 14, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. ( …
Coppernico Confirms Large-Scale Copper Skarn System and Expands Pipeline of Priority Targets at Sombrero
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF) (“Coppernico” or the “Company”), is pleased to report the remaining assay results from its Phase 1 drill program at its Sombrero Project in Peru. …
Calian annonce les résultats du deuxième trimestre
GlobeNewswire
·
May 14, 2025
(Tous les montants dans le communiqué sont en dollars canadiens.) OTTAWA, Ontario, 14 mai 2025 (GLOBE NEWSWIRE) -- CalianMD Group Ltd. (TSX : CGY), une société qui fournit des solutions essentielles à la mission, axée sur la défense, l’espace, les soins de …